In vivo molecular target assessment of matrix metalloproteinase inhibitionChristoph Bremer(Harvard University), Ching‐Hsuan Tung(Massachusetts General Hospital), Ralph Weissleder(Massachusetts General Hospital)Nature MedicineJune 1, 200110.1038/89126Cited by 731SaveCiteExport RISWatch citationsAbstractRelated PapersMatrix Metalloproteinases: Biologic Activity and Clinical ImplicationsAmy R. Nelson, Barbara Fingleton, Mace L. Rothenberg et al.|Journal of Clinical Oncology|2000|1.5kH-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen.Ivan E. Collier, S M Wilhelm, Arthur Z. Eisen et al.|Journal of Biological Chemistry|1988|1kTumor targeting with a selective gelatinase inhibitorErkki Koivunen, Wadih Arap, Heli Valtanen et al.|Nature Biotechnology|1999|580Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.B Davies, Jonathan Waxman, Harpreet Wasan et al.|PubMed|1993|427Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines.Peter de Nully Brown, Anna T. Levy, Inger Margulies et al.|PubMed|1990|383